B.Riley/FBR Resumes Akari Therapeutics (AKTX), Upgrade to Buy
Tweet Send to a Friend
B.Riley/FBR analyst Chad Mabry resumes coverage on Akari Therapeutics (NASDAQ: AKTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
